Menu

Blog

Page 7410

May 23, 2020

‘Herd immunity’ is impossible without a vaccine

Posted by in category: biotech/medical

The director of our institute, Sir Paul Nurse, borrowed another wartime analogy when he imagined academic labs as a flotilla of ‘little ships’, as at Dunkirk, that could be set up quickly to help rescue a rather desperate situation. The protocols we’ve developed have been downloaded more than 5,000 times, and we’ve helped other testing laboratories (including the big ones that are now coming online) with re-agents and scientific advice. We’ve been able to get recovering doctors and nurses back to work quicker, and crucially we’ve been able to identify healthcare workers who may have been spreading the virus unwittingly to the most vulnerable.

The team at the Crick is extremely multi-national. Wartime analogies are not helpful when they promote national exceptionalism, still less when they imply an individual battle between patient and virus. They are helpful when it comes to getting people to think clearly and act swiftly. The frustration when we’ve run up against what might be politely described as ‘NHS bureaucracy’ has been intense. When we’ve dealt with local NHS partners who are determined and dynamic, we’ve been able to save lives. In this sense there really is a war on, and for once I’m happy to see politicians treat it in this way.

We will win this war through immunity. Understanding immunity to respiratory viruses is really difficult — more like decoding Enigma than developing radar. We will need new technology as well as optimising existing tests. So far, the best tests can give a reasonable estimate of whether someone has been exposed to the virus. They cannot yet tell you if you are immune to it. The trouble with coronaviruses is that they have evolved to evade immunity. They possess all sorts of unknown weaponry that dampens down our immune responses.

May 23, 2020

General anesthetics activate a potent central pain-suppression circuit in the amygdala

Posted by in categories: biotech/medical, genetics, neuroscience

General anesthesia (GA) can produce analgesia (loss of pain) independent of inducing loss of consciousness, but the underlying mechanisms remain unclear. We hypothesized that GA suppresses pain in part by activating supraspinal analgesic circuits. We discovered a distinct population of GABAergic neurons activated by GA in the mouse central amygdala (CeAGA neurons). In vivo calcium imaging revealed that different GA drugs activate a shared ensemble of CeAGA neurons also possess basal activity that mostly reflects animals’ internal state rather than external stimuli. Optogenetic activation of CeAGA potently suppressed both pain-elicited reflexive and self-recuperating behaviors across sensory modalities and abolished neuropathic pain-induced mechanical (hyper-)sensitivity. Conversely, inhibition of CeAGA activity exacerbated pain, produced strong aversion and canceled the analgesic effect of low-dose ketamine. CeAGA neurons have widespread inhibitory projections to many affective pain-processing centers. Our study points to CeAGA as a potential powerful therapeutic target for alleviating chronic pain.

May 23, 2020

Remdesivir for the Treatment of Covid-19 — Preliminary Report

Posted by in category: biotech/medical

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness designated coronavirus disease 2019, or Covid-19.1 Several therapeutic agents have been evaluated for the treatment of Covid-19, but none have yet been shown to be efficacious.2,3 Remdesivir (GS-5734), an inhibitor of the viral RNA-dependent, RNA polymerase with inhibitory activity against SARS-CoV and the Middle East respiratory syndrome (MERS-CoV),4–7 was identified early as a promising therapeutic candidate for Covid-19 because of its ability to inhibit SARS-CoV-2 in vitro.8 In addition, in nonhuman primate studies, remdesivir initiated 12 hours after inoculation with MERS-CoV9,10 reduced lung virus levels and lung damage.

To evaluate the clinical efficacy and safety of putative investigational therapeutic agents among hospitalized adults with laboratory-confirmed Covid-19, we designed an adaptive platform to rapidly conduct a series of phase 3, randomized, double-blind, placebo-controlled trials. Here, we describe the preliminary results of the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), in which we evaluated treatment with remdesivir as compared with placebo.

May 23, 2020

America’s cautious comeback

Posted by in category: mobile phones

Data from millions of smartphones tells us which parts of the country have reopened.

May 23, 2020

CROWS Remote Machine Gun System In Action

Posted by in categories: military, surveillance

U.S. Military Soldiers conduct training on the Common Remotely Operated Weapon Station (CROWS).

CROWS is a stabilized mount that contains a sensor suite and fire control software, allowing on-the-move target acquisition and first-burst target engagement. CROWS also features programmable target reference points for multiple locations, programmable sector surveillance scanning, automatic target ballistic lead, automatic target tracking, and programmable no-fire zones.

Continue reading “CROWS Remote Machine Gun System In Action” »

May 23, 2020

Omorodion Klinton Nosakhare added a new photo

Posted by in category: futurism

It was fun speaking on STC webinar today.

May 23, 2020

Moderna execs dumped nearly $30 million of stock after news of promising coronavirus vaccine

Posted by in categories: biotech/medical, business, finance

Moderna’s stock price skyrocketed as much as 30% on Monday after the biotech company announced promising early results for its coronavirus vaccine. As ordinary investors piled in, two insiders were quietly heading for the exits.

Moderna’s chief financial officer and chief medical officer executed options and sold nearly $30 million of shares combined on Monday and Tuesday, SEC filings reviewed by CNN Business show.

The sales occurred after Moderna (MRNA) excited Wall Street before markets opened Monday by announcing encouraging vaccine trial results. Moderna’s market value swelled to $29 billion — even though the company has no marketed products.

May 23, 2020

Long-lasting coronavirus disinfectant developed by Israeli researchers

Posted by in categories: biotech/medical, transportation

Scientists from the Technion Israel Institute of Technology in Haifa have developed “smart” disinfectants which not only destroy the coronavirus, but unlike other commonly used disinfectants that diminish rapidly, remains on surfaces for an extender period of time. “The materials we developed will be a game changer because they will block the cycle of infection from contaminated surfaces,” said Assistant Professor Shady Farah, head of the research group. “Infection from touching surfaces is a serious problem, especially in public places such as hospitals, factories, schools, shopping malls, and public transportation. Our polymers will make these places safer,” Farah added.


The coronavirus has been seen to last on surfaces upwards of 17 days, and common disinfecting break down rapidly. This new disinfectant is long-lasting.

May 23, 2020

Scientists are using quantum entanglement to fight the U.S.‘s second-deadliest disease

Posted by in categories: biotech/medical, quantum physics

Researchers have demonstrated a proof-of-concept design for a quantum radar that uses entangled photon pairs to detect objects.

May 23, 2020

Scientists solve half-century-old magnesium dimer mystery

Posted by in categories: chemistry, particle physics, quantum physics

Magnesium dimer (Mg2) is a fragile molecule consisting of two weakly interacting atoms held together by the laws of quantum mechanics. It has recently emerged as a potential probe for understanding fundamental phenomena at the intersection of chemistry and ultracold physics, but its use has been thwarted by a half-century-old enigma—five high-lying vibrational states that hold the key to understanding how the magnesium atoms interact but have eluded detection for 50 years.

The lowest fourteen Mg2 vibrational states were discovered in the 1970s, but both early and recent experiments should have observed a total of nineteen states. Like a quantum cold case, experimental efforts to find the last five failed, and Mg2 was almost forgotten. Until now.

Piotr Piecuch, Michigan State University Distinguished Professor and MSU Foundation Professor of chemistry, along with College of Natural Science Department of Chemistry graduate students Stephen H. Yuwono and Ilias Magoulas, developed new, computationally derived evidence that not only made a in first-principles quantum chemistry, but finally solved the 50-year-old Mg2 mystery.